These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 37707559)

  • 1. The effect of renal impairment and obesity on anti-Xa peak and trough levels in patients receiving therapeutic doses of nadroparin: a comparison with control patients.
    Mast L; Peeters MYM; Söhne M; Hackeng CM; Knibbe CAJ; van den Broek MPH
    Eur J Clin Pharmacol; 2023 Nov; 79(11):1537-1547. PubMed ID: 37707559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Smaller nadroparin dose reductions required for patients with renal impairment: A multicenter cohort study.
    van Uden RCAE; Jaspers TCC; Meijer K; van Stralen KJ; Maat B; Khorsand N; van Onzenoort HAW; Swart EL; Huls HJ; Mathôt RAA; Lukens MV; van den Bemt PMLA; Becker ML
    Thromb Res; 2024 Apr; 236():4-13. PubMed ID: 38377636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Critical appraisal of evidence for anti-Xa monitoring and dosing of low-molecular-weight heparin in renal insufficiency.
    van den Broek MPH; Verschueren MV; Knibbe CAJ
    Expert Rev Clin Pharmacol; 2022 Oct; 15(10):1155-1163. PubMed ID: 36189469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular- weight heparin for the treatment of venous thromboembolism.
    Wilson SJ; Wilbur K; Burton E; Anderson DR
    Haemostasis; 2001; 31(1):42-8. PubMed ID: 11408748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effect of Obesity on Anti-Xa Concentrations in Bariatric Patients.
    Schijns W; Deenen MJ; Aarts EO; Homan J; Janssen IMC; Berends FJ; Kaasjager KAH
    Obes Surg; 2018 Jul; 28(7):1997-2005. PubMed ID: 29404935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimising the Nadroparin Dose for Thromboprophylaxis During Hemodialysis by Developing a Population Pharmacodynamic Model Using Anti-Xa Levels.
    Jaspers TCC; Meijer CE; Vleming LJ; Franssen CFM; Diepstraten J; Lukens MV; van den Bemt PMLA; Maat B; Khorsand N; Touw DJ; Koomen JV
    Clin Pharmacokinet; 2022 Nov; 61(11):1559-1569. PubMed ID: 36040615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacodynamic model for low molecular weight heparin nadroparin in morbidly obese and non-obese patients using anti-Xa levels as endpoint.
    Diepstraten J; Janssen EJ; Hackeng CM; van Dongen EP; Wiezer RJ; van Ramshorst B; Knibbe CA
    Eur J Clin Pharmacol; 2015 Jan; 71(1):25-34. PubMed ID: 25304008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of low-molecular-weight heparins on anti-Xa peak levels and adverse reactions in Chinese patients with recurrent spontaneous abortion: a single-center, observational study.
    Bai W; Zhang X; Sun S; Wang Q; Li C; Zhang X; Zhao A
    BMC Pregnancy Childbirth; 2021 Oct; 21(1):683. PubMed ID: 34620101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A case series of LMWH use in pregnancy: should trough anti-Xa levels guide dosing?
    Berresheim M; Wilkie J; Nerenberg KA; Ibrahim Q; Bungard TJ
    Thromb Res; 2014 Dec; 134(6):1234-40. PubMed ID: 25450535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No accumulation of a prophylactic dose of nadroparin in moderate renal insufficiency.
    Atiq F; van den Bemt PM; Leebeek FW; van Gelder T; Versmissen J
    Neth J Med; 2015 Oct; 73(8):373-8. PubMed ID: 26478547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring of anti-Xa in pregnant patients with mechanical prosthetic valves receiving low-molecular-weight heparin: peak or trough levels?
    Goland S; Schwartzenberg S; Fan J; Kozak N; Khatri N; Elkayam U
    J Cardiovasc Pharmacol Ther; 2014 Sep; 19(5):451-6. PubMed ID: 24607762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Description of anti-Xa monitoring practices during low molecular weight heparin use.
    Lin A; Vazquez SR; Jones AE; Witt DM
    J Thromb Thrombolysis; 2019 Nov; 48(4):623-628. PubMed ID: 31317300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dalteparin thromboprophylaxis for critically ill medical-surgical patients with renal insufficiency.
    Rabbat CG; Cook DJ; Crowther MA; McDonald E; Clarke F; Meade MO; Lee KA; Cook RJ
    J Crit Care; 2005 Dec; 20(4):357-63. PubMed ID: 16310608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The right time to measure anti-Xa activity in critical illness: pharmacokinetics of therapeutic dose nadroparin.
    Sytema JG; Loef BG; Loovers HM; Boer M; Touw DJ; van Hulst M
    Res Pract Thromb Haemost; 2023 May; 7(4):100185. PubMed ID: 37449055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency.
    Lim W; Dentali F; Eikelboom JW; Crowther MA
    Ann Intern Med; 2006 May; 144(9):673-84. PubMed ID: 16670137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nadroparin versus dalteparin anticoagulation in high-volume, continuous venovenous hemofiltration: a double-blind, randomized, crossover study.
    de Pont AC; Oudemans-van Straaten HM; Roozendaal KJ; Zandstra DF
    Crit Care Med; 2000 Feb; 28(2):421-5. PubMed ID: 10708177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-Xa activity in obese patients after double standard dose of nadroparin for prophylaxis.
    Heizmann M; Baerlocher GM; Steinmann F; Horber FF; Wuillemin W
    Thromb Res; 2002 May; 106(4-5):179-81. PubMed ID: 12297122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Weight-Based Enoxaparin Achieves Adequate Anti-Xa Levels More Often in Trauma Patients: A Prospective Study.
    Stutsrim AE; Eady JM; Collum M; Rebo GJ; Rebo KA; Miller PR; Nunn AM
    Am Surg; 2021 Jan; 87(1):77-82. PubMed ID: 32915054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamics and tolerance of two nadroparin formulations (10,250 and 20,500 anti Xa IU x ml(-1)) delivered for 10 days at therapeutic dose.
    Boneu B; Navarro C; Cambus JP; Caplain H; d'Azemar P; Necciari J; Duret JP; Gaud C; Sié P
    Thromb Haemost; 1998 Feb; 79(2):338-41. PubMed ID: 9493587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose effect relationship of reviparin in chronic hemodialysis: a crossover study versus nadroparin.
    Reach I; Luong N; Chastang C; Chakroun M; Mirshahi S; Mirshahi MC; Soria J; Desmichels D; Baumelou A
    Artif Organs; 2001 Jul; 25(7):591-5. PubMed ID: 11493282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.